Patents by Inventor Chi-Ming Kevin LI

Chi-Ming Kevin LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF LILRB1/2 PATHWAY INHIBITORS AND PD-1 PATHWAY INHIBITORS
    Publication number: 20210301020
    Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 30, 2021
    Applicant: AMGEN INC.
    Inventors: Xin YU, Wenjun OUYANG, Chi-Ming Kevin LI, Jackson Graeme EGEN, Oh Kyu YOON, Ian Halsey DRIVER, Shunsuke TAKENAKA, Christy Ann THOMSON, Hongyu WANG
  • Promoter and regulatory elements for improved expression of heterologous genes in host cells
    Patent number: 10202616
    Abstract: Disclosed are a recombinant expression vector and a host cell that contains the vector.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: February 12, 2019
    Assignee: AMGEN INC.
    Inventors: Mark Daris, Jennitte LeAnn Stevens, Chi-Ming Kevin Li, Huanying Ge
  • Promoter and Regulatory Elements for Improved Expression of Heterologous Genes in Host Cells
    Publication number: 20170253889
    Abstract: Disclosed are a recombinant expression vector and a host cell that contains the vector.
    Type: Application
    Filed: October 14, 2015
    Publication date: September 7, 2017
    Applicant: AMGEN INC.
    Inventors: Mark DARIS, Jennitte LeAnn STEVENS, Chi-Ming Kevin LI, Huanying GE